This publication describes the development of a universal demonstration technology based on osmotic capsules to rapidly assess dosage-form development for a given API. These capsules were designed to accommodate different release profiles and additives with minimal formulation optimization. While it is recognized that this rapid demonstration technology can be supplanted with other technologies for commercialization, use of the platform shortened overall time to market by rapidly defining drug-related factors before spending the time and resources on development of the eventual commercial dosage form.
Please note that Lonza has updated its Privacy Policy. By visiting our website or using services provided by Lonza, you are accepting the practices described in the Privacy Policy.
We also use cookies on our websites. Cookies allow us to give you the best browsing experience and help us to understand how you use our site. You can disable cookies but parts of our website may not work. Please read our updated Cookies Policy for information about which cookies we use and the information we collect. By continuing to use this website, you agree that we may store and access cookies on your device.
By clicking "I Agree", you confirm that you are above the age of 16, that you have read and understood the Privacy Policy and the Cookies Policy, and that you agree to the collection, use and processing of your Personal Information by Lonza in accordance with said policies.